Tolvaptan slows disease progression in late-stage ADPKD

被引：11

作者：

Ong, Albert C. M. ^{[1
]}

机构：

[1] Univ Sheffield, Med Sch, Dept Infect Immun & Cardiovasc Dis, Acad Nephrol Unit, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England

来源：

NATURE REVIEWS NEPHROLOGY | 2018年 / 14卷 / 03期

关键词：

POLYCYSTIC KIDNEY-DISEASE; TEMPO; 3/4; TRIAL;

D O I：

10.1038/nrneph.2017.180

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

New data from the REPRISE trial confirms that tolvaptan slows the progression of autosomal dominant polycystic disease (ADPKD). Although not yet approved by the United States Food and Drug administration, tolvaptan is now likely to become standard care for early and later stages of ADPKD in Europe and in various countries worldwide.

引用

页码：147 / 148

页数：2

共 10 条

[1] [Anonymous], NEPHROL DIAL TRANSPL
[2] Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial
Devuyst, Olivier
Chapman, Arlene B.
Gansevoort, Ron T.
Higashihara, Eiji
Perrone, Ronald D.
Torres, Vicente E.
Blais, Jaime D.
Zhou, Wen
Ouyang, John
Czerwiec, Frank S.
[J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 28 (05): : 1592 - 1602
[3] Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice
Gansevoort, Ron T.
Arici, Mustafa
Benzing, Thomas
Birn, Henrik
Capasso, Giovambattista
Covic, Adrian
Devuyst, Olivier
Drechsler, Christiane
Eckardt, Kai-Uwe
Emma, Francesco
Knebelmann, Bertrand
Le Meur, Yannick
Massy, Ziad A.
Ong, Albert C. M.
Ortiz, Alberto
Schaefer, Franz
Torra, Roser
Vanholder, Raymond
Wiecek, Andrzej
Zoccali, Carmine
Van Biesen, Wim
[J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 (03) : 337 - 348
[4] The importance of total kidney volume in evaluating progression of polycystic kidney disease
Grantham, Jared J.
Torres, Vicente E.
[J]. NATURE REVIEWS NEPHROLOGY, 2016, 12 (11) : 667 - 677
[5] Mao Zhiguo, 2016, F1000Res, V5, P2029, DOI 10.12688/f1000research.9045.1
[6] Autosomal dominant polycystic kidney disease: the changing face of clinical management
Ong, Albert C. M.
Devuyst, Olivier
Knebelmann, Bertrand
Walz, Gerd
[J]. LANCET, 2015, 385 (9981) : 1993 - 2002
[7] Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease
Spithoven, Edwin M.
Kramer, Anneke
Meijer, Esther
Orskov, Bjarne
Wanner, Christoph
Caskey, Fergus
Collart, Frederic
Finne, Patrik
Fogarty, Damian G.
Groothoff, Jaap W.
Hoitsma, Andries
Nogier, Marie-Beatrice
Postorino, Maurizio
Ravani, Pietro
Zurriaga, Oscar
Jager, Kitty J.
Gansevoort, Ron T.
[J]. KIDNEY INTERNATIONAL, 2014, 86 (06) : 1244 - 1252
[8] Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
Torres, Vicente E.
Chapman, Arlene B.
Devuyst, Olivier
Gansevoort, Ron T.
Perrone, Ronald D.
Koch, Gary
Ouyang, John
McQuade, Robert D.
Blais, Jaime D.
Czerwiec, Frank S.
Sergeyeva, Olga
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) : 1930 - 1942
[9] Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial
Torres, Vicente E.
Higashihara, Eiji
Devuyst, Olivier
Chapman, Arlene B.
Gansevoort, Ronald T.
Grantham, Jared J.
Perrone, Ronald D.
Ouyang, John
Blais, Jaime D.
Czerwiec, Frank S.
[J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2016, 11 (05): : 803 - 811
[10] Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
Torres, Vicente E.
Chapman, Arlene B.
Devuyst, Olivier
Gansevoort, Ron T.
Grantham, Jared J.
Higashihara, Eiji
Perrone, Ronald D.
Krasa, Holly B.
Ouyang, John
Czerwiec, Frank S.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (25) : 2407 - 2418

← 1 →